GCM
UTHR icon

Gladius Capital Management’s United Therapeutics UTHR Stock Holding History

Gladius Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-301
Closed -$71K – 504
2022
Q2 		$71K Buy
+301
New +$61.2K ﹤0.01% 226

Other funds holding UTHR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Gladius Capital Management's UTHR Position: Q3 2022 in Review

Gladius Capital Management sold out of United Therapeutics (UTHR) in Q3 2022, closing a stake of 301 shares — an estimated $71K sold.

Gladius Capital Management first reported a position in UTHR in Q2 2022 and held it in 1 quarter. The position peaked at $71K in Q2 2022. 459 funds tracked by Wall St. Rank hold UTHR as of Q3 2022.

  • Gladius Capital Management reported no remaining United Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Gladius Capital Management sold 301 United Therapeutics shares in Q3 2022, an estimated $71K.
  • Gladius Capital Management first reported a position in United Therapeutics in Q2 2022 and held it in 1 quarter.
  • Gladius Capital Management's United Therapeutics position peaked at $71K in Q2 2022.
  • 459 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2022.

Based on Gladius Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.